Foundayo Tablet, Film Coated
Product Images NDC 0002-4839

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Foundayo (NDC 0002-4839). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eli Lilly And Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Foundayo (orforglipron) Tablets 0.8 mg 30 Count Package (Fou 0.8mg Cart 791057)

FDA Label Image

Foundayo (orforglipron) Tablets 14.5 mg 30 Count Package (Fou 14.5mg Cart 791070)

FDA Label Image

Foundayo (orforglipron) Tablets 17.2 mg 30 Count Package (Fou 17.2mg Cart 791071)

FDA Label Image

Foundayo (orforglipron) Tablets 2.5 mg 30 Count Package (Fou 2.5mg Cart 791063)

This text appears to be product information for "Foundayo" tablets containing orforglipron. The tablets contain 2.5 mg of orforglipron and are to be kept at room temperature. The product is marketed by Lily USA, LLC in Indianapolis, Indiana. The tablets are to be dispensed with an enclosed Medication Guide. Each pack contains 30 tablets.*

FDA Label Image

Foundayo (orforglipron) Tablets 5.5 mg 30 Count Package (Fou 5.5mg Cart 791065)

FDA Label Image

Foundayo (orforglipron) Tablets 9 mg 30 Count Package (Fou 9mg Cart 791068)

FDA Label Image

Chemical Structure (Fou Uspi Chem V1)

FDA Label Image

Figure 1 (Fou Uspi F1 V1)

This text shows a comparison between different doses of a drug called FOUNDAYO (5mg, 9mg, 17.2mg) and a placebo. It presents the number of patients in each group measured at various time points over weeks post-randomization. The data suggests observations related to the effects of the drug on the patients.*

FDA Label Image

Figure 2 (Fou Uspi F2 V1)

The text describes a study comparing the effectiveness of three different doses of a drug called FOUNDAYO (at 5.5mg, 9mg, 17.2mg) with a placebo. The number of patients in each group at various weeks post-randomization is also provided. This information can be used to evaluate the efficacy of different dosages of the drug in comparison to the placebo.*

FDA Label Image

Figure 3 (Fou Uspi F3 V1)

FDA Label Image

Figure 4 (Fou Uspi F4 V1)

This description provides a breakdown of the cumulative frequency (%) for various values, along with a visual representation showing the change in body weight (%) for different dosages of a substance and a placebo. The data includes values such as -55, -50, -45, and positive values up to 35. The analysis seems to be related to the effect of different doses (5.5 mg, 17.2 mg, 9 mg) of a substance compared to a placebo on body weight changes.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.